ARS Pharmaceuticals (SPRY) Return on Capital Employed (2021 - 2026)
ARS Pharmaceuticals (SPRY) posted Return on Capital Employed of 78.46% for Q1 2026, down 36.01% sequentially from 57.69% in Q4 2025, and down 6977.0% YoY from 1.14% in Q1 2025.
ARS Pharmaceuticals (SPRY) Return on Capital Employed (2021 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Return on Capital Employed for 6 years, with the latest figure at 78.46% in Q1 2026.
- Quarterly Return on Capital Employed fell 6977.0% year-over-year to 78.46% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 78.46% (down 6977.0% YoY) and the FY2025 annual result came in at 59.76%, down 5862.0% from the prior year.
- Return on Capital Employed declined to 78.46% in Q1 2026 per SPRY's latest filing, from 57.69% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 9.53% in Q3 2022 and troughed at 78.46% in Q1 2026.
- A 5-year average of 22.73% and a median of 24.08% in 2023 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2026: Return on Capital Employed surged 3252 bps in 2022, then slumped 6977 bps in 2026.
- Over 5 years, Return on Capital Employed stood at 13.11% in 2022, then plunged by 116 bps to 28.31% in 2023, then surged by 96 bps to 1.18% in 2024, then tumbled by 4782 bps to 57.69% in 2025, then tumbled by 36 bps to 78.46% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 78.46%, 57.69%, and 31.06% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | -104.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -104.14% |
| Mar 31, 2026 | -78.46% |
| Dec 31, 2025 | -57.69% |
| Sep 30, 2025 | -31.06% |
| Jun 30, 2025 | -21.59% |
| Mar 31, 2025 | -8.69% |
| Dec 31, 2024 | -1.18% |
| Sep 30, 2024 | -29.78% |
| Jun 30, 2024 | -26.02% |
| Mar 31, 2024 | -27.35% |
| Dec 31, 2023 | -28.31% |
| Sep 30, 2023 | -30.00% |
| Jun 30, 2023 | -24.08% |
| Mar 31, 2023 | -17.69% |
| Dec 31, 2022 | -13.11% |
| Sep 30, 2022 | 9.53% |
| Jun 30, 2022 | 3.59% |
| Mar 31, 2022 | -4.45% |
| Dec 31, 2021 | -9.78% |
| Sep 30, 2021 | -22.99% |